Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 5/20 | 0.57 |
| ▸ | SQLE | Q14534 | 4/20 | 0.57 |
| ▸ | FNTB | P49356 | 3/20 | 0.57 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11617759 | 1.00 | KMT2A (0.67) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL1704911 | 1.00 | KMT2A (0.67) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL12967956 | 1.00 | KMT2A (0.67) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL15980978 | 1.00 | KMT2A (0.67) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL15980982 | 1.00 | KMT2A (0.67) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL10127135 | 1.00 | KMT2A (0.67) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL356732 | 0.98 | KMT2A (0.62) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL114887 | 0.98 | KMT2A (0.62) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL114886 | 0.98 | KMT2A (0.62) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL11039524 | 0.88 | SQLE (0.54) | KMT2AALOX15ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-08-28 | — | — | US | disclosed |
| US-7897736-B2 | Fluorescent quenching detecting reagents and methods | ELITECH HOLDING B.V. (NL) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | WEE1, WEE2, NOTUM | KMT2A 3869/4885ALOX15 161/4885ALDH1A1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.